Thus, the targeted degradation of STING by tumor cells “undoes”, at least in part, the efforts of cisplatin-induced cGAS activation, leading to incomplete activation of cGAS-STING in the direction of immunosuppressive TME, which ultimately requires additional STING agonists to achieve the desired therapeutic effect. Here, CGAS is linked to neoplasm.